阿托伐他汀治疗急性呼吸窘迫综合征的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the clinical efficacy of Atorvastatin in the treatment of acute respiratory distress syndrome(ARDS).MethodsAltogether 50 patients with ARDS who were treated in intensive care unit(ICU)of our hospital from January 2015 to December 2016 were selected as subjects and randomly divided into the control group(n=25)and the observation group　(n=25)according to the random number table method.The control group was given mechanical ventilation to adjust the positive pressure of the terminal respiration and the oxygen concentration,the control group was also given etiological treatment of primary diseases and anti-infective treatment based on reasonable application.On the basis of the control group,the observation group was fed with Atorvastatin Tablets by the nose at night,40 mg per day,and was treated for 28 days.The levels of C-reactive protein,complement C3,complement C4,CD4+/CD8+,cholesterol,triacylglycerol,low-density lipoprotein and high-density lipoprotein were compared and observed.And the time of mechanical ventilation,stay in intensive care unit(ICU)and length of stay in hospital were compared between two groups.ResultsAfter treatment,the C-reactive protein level of the observation group was lower than that of the control group　(P＜0.05).No statistically significant difference was seen between two groups in the complement C3,C4 and CD4+/CD8+(P＞0.05).The cholesterol,triacylglycerol,low-density lipoprotein and high-density lipoprotein of the observation group were lower than those of the control group,with statistically significant difference　(P＜0.05).After treatment,the time of mechanical ventilation,stay in intensive care unit(ICU)and length of stay in hospital of the observation group were all shorter than those of the control group,with statistically significant difference　(P＜0.05).ConclusionAtorvastatin can reduce the inflammatory reaction of ARDS patients and improve patients′immunity and prognosis,which has certain clinical application value.

Key words： Respiratory distress syndrome Adult Inflammation Atorvastatin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Sheng-rong
	HU Xing-zhou
	JIN Hui-chun
	XU Su-ping
	CHEN Xiao-li

Cite this article:

ZHANG Sheng-rong,HU Xing-zhou,JIN Hui-chun, et al. Clinical effect of Atorvastatin in the treatment of acute respiratory distress syndrome[J]. 中国当代医药, 2018, 25(18): 97-99.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I18/97

[1]	Heart N.Randomized，placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury[J].Am J Respir Crit Care Med，2011，184（5）：561-568.
[2]	Gao FS，Perkins GD，Gates S，et al.Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome　（BALTI-2）：a multicentre，randomised controlles trial[J].Lancet，2012，379（9812）：229-235.
[3]	Shyamsundar M，McKeown ST，O′Kane CM，et al.Simvastatin decreases lipopolysaccharide-induced pulmonary inflammationinhealthyvolunteers[J].AmJRespirCritCareMed，2009，179（12）：1107-1114.
[5]	郭献阳，张明，陈如杰，等.辛伐他汀治疗急性呼吸窘迫综合征的临床研究[J].中国临床药理学，2015，31（6）：406-408.
[8]	何涛，张剑珲.辛伐他汀对脓毒症早期大鼠肝脏损害的影响[J].中国中西医结合急救杂志，2012，19（5）：283-286.
[9]	李全忠，孙婧，韩金杰，等.辛伐他汀对小鼠炎症型巨噬细胞极性的影响[J].中华医学杂志，2013，93（26）：2071-2074.
[4]	Craig TR，Duffy MJ，Shyamsundar M，et al.A randomized clinical trial of hydroxymethylglutaryl-coenzyme a reductase inhibition for acute lung injury （The HARP Study）[J].Am J Respir Crit Care Med，2011，183（5）：620-626.
[6]	Craig TR，Duffy MJ，Shyamsundar M，et al.A randomized clinical trial of hydroxymethylglutaryl-coenzyme a reductase inhibition for acute lung injury （The HARP Study）[J].Am J Respir Crit Care Med，2011，183（5）：620-626.
[7]	Husari AW，Khayat A，Awdeh H，et al.Activated protein C attenuates acute lung injury and apoptosis in a hyperoxic animal model[J].Shock，2010，33（5）：467-472.
[10]	汪日红，郑霞，姜赛平，等.辛伐他汀纳米粒降低脂多糖诱导人脐静脉内皮细胞损伤的初步研究[J].中华急诊医学杂志，2013，22（10）：1123-1127.
[11]	戴新贵，付春来，蔡业平，等.辛伐他汀对脓毒症并发ARDS患者CD4+、CD25+调节性T细胞的影响[J].中国实用医药，2015，10（7）：6-8.
[12]	王咏梅.不同剂量辛伐他汀对急性心肌梗死患者的炎性反应以及凝血机制的影响[J].泰山医学院学报，2010，31（10）：776-778.
[13]	蒋桦，夏春香，李季忱，等.辛伐他汀对急性心肌梗死患者炎症水平和内皮功能的影响[J].血栓与止血学，2014，20（2）：65-67.
[14]	郭献阳，张明，魏大臻，等.辛伐他汀对中重度急性呼吸窘迫综合征患者炎性反应及凝血功能的影响[J].2015，18（16）：1931-1935.
[15]	赵鹤龄，任珊，申丽旻.辛伐他汀预处理对脓毒症大鼠凝血功能及肝脏C-反应蛋白的影响[J].中国急救医学，2012，32（8）：718-721.